Genentech, a biotechnology firm based in San Francisco and a subsidiary of Roche, plans to invest up to $700 million to establish a new manufacturing facility in Holly Springs, North Carolina, creating up to 420 high-paying jobs by 2030. This facility, the company’s first on the East Coast and its first new manufacturing site globally in two decades, will focus on developing obesity drugs. The project is anticipated to contribute $3.1 billion to the state’s economy over 12 years, supported by an incentives package of up to $13.1 million. Holly Springs has become a hub for biotech expansion, with other companies like Amgen and FujiFilm Diosynth also ramping up their operations in the area.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.wral.com/archive/22002862/
